5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of February 2018. Valeant was also able to highlight rebounding sales for gastrointestinal-disease drug Xifaxan.
But while Valeant reported some positives, there was plenty in the company's update that continues to be of concern for investors. Here are five things management said in the company's second-quarter conference call that suggest the situation is getting worse for the drugmaker. (Quotes from S&P Global Market Intelligence.)
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
5,73 €
-3,05 %
Die Community unterstützt Bausch Health Companies Inc. leicht, mit mehr Buy- als Sell-Einschätzungen.
Das durchschnittliche Community-Kursziel von 16 € für Bausch Health Companies Inc. deutet auf eine Verdopplung des aktuellen Kurses von 5.73 € hin.
